Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30241 ↗At a glance
Leserbrief in Pediatric Blood & Cancer, 2023. Written by Katelyn N Swizer and 2 co-authors. Institution: Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Down Syndrome. Cited 1 times so far (Crossref); 12 references.
Abstract (original language)
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon immunologic disorder associated with high rates of morbidity and mortality characterized by systemic inflammation and multiorgan dysfunction. The standard of care for primary treatment of HLH is chemotherapy (i.e. etoposide), but consideration of alternative therapies is warranted to support treatment goals for critically ill pediatric patients. We present the case of a 7-year-old male with trisomy 21, acute multiorgan failure secondary to infection, and subsequent HLH who was successfully treated with ruxolitinib. This represents the first use of ruxolitinib as a first-line agent for secondary HLH in a critically ill child with trisomy 21.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA.
- Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID profiles: Miriam B Garcia
Cite
APA
Swizer, K. N., Beebe, M., & Garcia, M. B. (2023). Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30241
Vancouver
Swizer KN, Beebe M, Garcia MB. Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30241
BibTeX
@article{Swizer2023,
author = {Swizer, Katelyn N and Beebe, Morgan and Garcia, Miriam B},
title = {Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30241}
}
EUVIMED